Despite a dip in revenue, Allurion Technologies Inc (ALUR) showcases strategic advancements and a robust plan for future growth.

Hello, everyone, and welcome to Allurion fourth quarter earnings call. Please note that this call is being recorded. After the speaker's prepared remarks, there will be a question and answer session.

Shares of Allurion Technologies, Inc. (ALUR) tumbled nearly 11% on Wednesday morning after the company’s fourth-quarter (Q4) ...

Forman, and Allurion Technologies are the five Small Cap stocks to watch today, according to MarketBeat’s stock screener tool ...

Allurion Technologies (NYSE:ALUR – Get Free Report) is anticipated to release its earnings data before the market opens on ...

Shares of Allurion Technologies on Friday surged a day after the company said it received positive results about the effectiveness of its gastric balloon in combination with a low dose of the ...

US stock futures were tracking lower in Friday's premarket session as Dow Jones Industrial Average futures were down 0.26%, S&P 500 futures were off 0.24%, and Nasdaq futures declined 0.32%. Although ...

Chardan notes that Allurion has announced additional data evaluating the use of its Allurion Balloon in combination with patients be treated ...

Roth MKM keeps a Buy rating and $16 price target on Allurion Technologies (ALUR) after its initial results from Allurion Program-GLP-1 combo.

Allurion Technologies' gastric balloon and Novo Nordisk's semaglutide achieved 20.3% weight loss in a trial. Read more here.

The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including ...